Category:
Chiral Intermediates
CAS NO:
2222755-14-6
Standard:
ChP,In-house Standards,

Loxo-292 is one such oral, highly selective drug in development that can target tumors with mutations in the RET gene. It inhibits natural RET signaling and the expected acquired resistance mechanism, which enables the activity of the therapy.